A Study of Replagal in Children and Adults With Fabry Disease in India
A Prospective, Open-label, Multicentre, Interventional, Single-arm, Phase IV Study to Evaluate the Safety and Efficacy of Replagal (Agalsidase Alfa [r-DNA Origin]) in Indian Children and Adults With Fabry Disease
Sponsor: Shire
A PHASE4 clinical study on Fabry Disease, this trial is actively recruiting participants. The trial is conducted by Shire and has accumulated 12 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE4
Status: Active Not Recruiting → Recruiting
-
Aug 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE4
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Apr 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2022 — Mar 2022 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .